Introduction
Annual data reports show that the prevalence of end-stage renal disease (ESRD) is increasing in the USA and Japan. 1, 2 End-stage renal disease is defined as measured or estimated glomerular filtration rate of ,15 mL/min/1.73 m 2 or on dialysis. Approximately half million patients were either on dialysis or had undergone transplant, and 350,000 (70%) of these patients were dialysis patients in the USA. 1 Approximately 250,000 patients were on dialysis in Japan. 2 Compared with the previous year, there was a moderate increase in the number of dialysis patients both in the USA and Japan (increases of 3.4 and 4.0%, respectively). In addition, the number of patients returning to dialysis after a failed kidney transplant also increased reaching 5578 patients in the year 2006 (a 34% increase since 2000) in the USA. 1 Patients with ESRD have a high mortality rate (annually 20-30% in the USA and 10% in Japan) and the appropriate choice of treatments for these patients is an important medical issue worldwide. 1, 2 End-stage renal disease while on haemodialysis (HD) is an important risk factor for mortality and clinical outcome after percutaneous coronary intervention (PCI) in patients with coronary artery disease. 3 -8 Furthermore, PCI in HD patients is more complex and difficult to perform than in non-haemodialysis (NH) patients because of massive coronary calcification and presence of multiple lesions. 9, 10 Previous randomized trials have shown that the use of sirolimus-eluting stents (SES, Cypher TM stent; Johnson & Johnson/Cordis, Miami, FL, USA) markedly reduce the risk of in-stent restenosis compared with standard bare-metal stents (BMS). However, patients with ESRD have been excluded from previous randomized trials. 11 -14 The use of SES has been recently reported to remarkably reduce restenosis after implantation in patients at high risk for in-stent restenosis compared with BMS in the real world. 15 -20 However, it remains unclear whether the use of SES after PCI in HD patients has long-term efficacy and safety similar to those of NH patients. In the present study, the 3-year clinical outcome after PCI with SES in HD patients was compared with that of NH patients in the Japan multi-centre post-marketing surveillance registry.
Methods

Study design and patients selection
We analysed the medical records of 2050 consecutive patients who underwent PCI with SES at 50 institutions in Japan from September 2004 to September 2005. Only patients treated with SES during this period were included in the study. Patients were divided into HD (n ¼ 106) and NH (n ¼ 1944) groups. All patients in the HD group had established ESRD and had already been on HD before PCI. Risk factors and history of previous cardiovascular disease were reviewed. Diabetes mellitus (DM) was defined as hyperglycaemia requiring insulin and/or oral hypoglycaemic drug treatment, according to Japan Diabetic Society diagnostic criteria for DM (fasting blood glucose .126 mg/dL, or random blood glucose or 2 h blood glucose in a 75 g oral glucose tolerance test of .200 mg/dL). Hyperlipidaemia was defined as receiving lipid-lowering therapy and/or the presence of a total serum cholesterol ≥220 mg/dL or serum triglycerides ≥150 mg/dL. Hypertension was defined as receiving medication to lower blood pressure or measured blood pressure values of ≥140 mmHg systolic or ≥90 mmHg diastolic on two or more occasions. The left ventricular ejection fraction (LVEF) was measured by echocardiography or angiography during hospitalization.
Procedures
Percutaneous coronary intervention was performed following the current clinical practice standards after obtaining written, informed consent. Patients received single or multiple SES for various lesions with or without predilatation or the use of ablative devices for plaque modification. Intravascular ultrasound (IVUS) was employed for guiding the procedure in 72.3% (1482/2050) of cases. After SES implantation, angiographic optimization was performed by highpressure dilatation to achieve an acceptable angiographic result with ,30% residual stenosis. All patients received aspirin 81 -200 mg/day before the procedure, and it was continued indefinitely. Additional antiplatelet therapy with 200 mg ticlopidine daily was instituted in all patients except two patients who were treated with 75 mg clopidogrel daily. They were advised to continue for at least 3 months. The rates of aspirin and ticlopidine (or clopidogrel) usages at the end of the 3-year follow-up were 85.1 and 41.3%, respectively. Glycoprotein IIb/IIIa inhibitor was not used because it is not approved in Japan.
Outcome definitions
After discharge, patients were clinically followed up by medical appointment at 3 , The primary endpoint for this analysis was cardiac death or TLR during the time frame from stent implantation until the end of the 3-year follow-up. The secondary endpoint for this analysis was the occurrence of all-cause death, ST, MI, TVR, non-target-lesion TVR, TVF, or MACE during the time frame from stent implantation until the end of the 3-year follow-up.
Clinical follow-up
A dedicated data coordinating centre performed the data management and analyses. Follow-up information of the study population was obtained from outpatient clinic visits, a review of the medical records, or a telephone interview with the patient. The follow-up rate of angiography at 8 months was 85.4% and follow-up rates of clinical outcomes at 1-, 2-, and 3 years were 97.9, 97.1, and 94.7%, respectively. All MACEs were confirmed by independent board physicians who were not involved in the procedures.
Statistical analysis
The clinical and angiographic characteristics and the proportion of MACE were compared between the two groups. Continuous data were expressed as mean + SD. The Wilcoxon rank sum test was used to compare continuous variables and Fisher's exact test was used to compare categorical variables. A P -value ,0.05 was considered to be of statistical significance. All reported P-values are twosided. Event-free survival curves were constructed using Kaplan-Meier curves. These curves were compared using the log-rank test. To adjust for potential confounders, a propensity score analysis was performed by use of logistic regression models. It was reported that the bias of propensity score model depended on the strength of the association of exposure with the outcome; however, it did not depend on the number of events per confounder variables. 21 Therefore, we tested all available variables that were thought to be of potential relevance, such as age, gender, indication of PCI, previous MI, previous PCI, previous CABG, diabetes, insulin-treated diabetes, hyperlipidaemia, hypertension, family history of coronary artery disease, current smoker, obesity, cerebrovascular disease, peripheral vascular disease, multivessel disease, target vessel, ACC/AHA classification type B2/C, in stent restenosis, bifurcation, eccentric, lesion angulation ≥458, moderate/severe calcification, ostial, total occlusion, chronic total occlusion, IVUS usage, direct stenting, Rotablator, total stent length, number of SES deployment, number of lesion, post dilatation, reference vessel diameter, lesion length, and percent diameter stenosis (%DS) after procedure. The score was then incorporated into subsequent proportional-hazard models as a covariate. Cox's proportional-hazard models adjusted with the propensity score were also used to assess the relative risks of cardiac death and TLR. Propensity score-adjusted event-free survival curves were also constructed. We conducted Cox's proportional-hazard model to identify independent risk factors of cardiac death and TLR in all patients, the HD group and the NH group to 3 years. The variables of multivariate analysis were determined by stepwise selection with an entry and exit criterion for each candidate of P , 0.100 from patients' background and lesion characteristics. Quantitative coronary analyses were performed using the CASSII software (Pie Medical) or QCA-CMS software (MEDIS). All analyses were performed using SAS version 9.1 for Windows (SAS Institute, Cary, NC, USA).
Results
Clinical findings
The patients' baseline clinical characteristics are summarized in Table 1 . There were no significant differences in mean age, gender distribution, and the prevalence of previous MI and previous PCI between the two groups. There was a higher prevalence of the LVEF ,30% (P , 0.001), previous CABG (P ¼ 0.015), DM (P , 0.001), and peripheral vascular disease (P ¼ 0.003) in the HD group, while patients in the NH group had a higher prevalence of obesity (P , 0.001) and hyperlipidaemia (P , 0.001). Furthermore, the HD group had a higher incidence of multi-vessel disease (P ¼ 0.015).
Angiographic characteristics
The angiographic and procedural characteristics are shown in Table 2 . The HD group had a significantly higher incidence of right coronary artery lesions while the NH group had a significantly higher incidence of left anterior descending artery lesions. The HD group had a significantly higher incidence of ACC/AHA classification type B2/C lesions, eccentric lesions, and moderate/severe calcification lesions. In terms of procedural characteristics, the HD group had a greater use of rotational atherectomy and a higher mean maximum deployment pressure while it had a lower frequency of direct stenting. There were no significant differences in the frequency of IVUS usage, overlapping stenting, diameter of stent, total stent length, and stent/patient and stent/lesion ratios.
Quantitative coronary analyses at baseline and at 8 months of follow-up
There was a significant difference in the angiographic follow-up rate between HD and NH groups (HD: 71.7 vs. NH: 86.2%; P , 0.001). The HD group had a higher drop-out rate of follow-up angiography because of a higher death rate or hesitation to undergo angiography compared with the NH group. Therefore, elective angiographic follow-up rates were distributed unequally between the two groups. The HD group had a larger mean minimal luminal diameter with a larger mean reference diameter at baseline. Mean minimal luminal diameter after procedure, %DS before and after procedure, and acute gain were similar between the two groups. After 8 months of follow-up, the HD group had a smaller mean minimal luminal diameter and larger %DS. Consequently, mean late loss and binary restenosis rates in the HD group were higher than those in the NH group (late loss: 0.49 + 0.89 vs. 0.14 + 0.56 mm; binary restenosis: 26.4 vs. 8.2%, respectively; P , 0.001 for both) ( Table 3) .
Clinical follow-up at 3 years
The clinical outcomes are presented in Table 4 . At the 3-year follow-up, the primary outcomes of cardiac mortality and TLR rates, and the secondary outcomes of all-cause mortality, MACE, TVR, non-target-lesion TVR, and TVF were all significantly higher for the HD group than the NH group. On the other hand, there was no statistically significant difference in MI rate between the two groups at 3 years. The difference in ST rate between the two groups (HD: 2.0 vs. NH: 0.7%) did not reach statistical significance at 3 years. Figure 1 shows the 3 year Kaplan-Meier plots of event-free survival for TLR ( Figure 1A ), all-cause death ( Figure 1B) , cardiac death ( Figure 1C) , and MACE ( Figure 1D) Figure 2 shows comparisons of propensity score-adjusted 3 year cumulative incidence curves for cardiac death and TLR for the HD and the NH groups. The HD group had a significantly higher risk of TLR (HD: 16.3 vs. NH: 6.1%; P ¼ 0.0003; Figure 2A ) and a significantly higher risk of Figure 2B ). By additional analysis matching HD patients with NH patients, we also found that the rates of cardiac death and TLR in matching HD patients were significantly higher than those of matching NH patients (HD: 13.8 vs. NH: 3.1% for cardiac death, P ¼ 0.006; HD: 12.5 vs. NH: 4.61% for TLR, P ¼ 0.029). In short, HD was strongly associated with cardiac events, such as cardiac death or TLR after SES implantation.
Independent risk factors of cardiac death and TLR to 3 years of follow-up
The multivariate analysis of independent risk factors for all patients showed that HD 
Discussion
In the present study, we have demonstrated that, (i) SESs have a significantly higher incidence of MACE in HD patients compared with NH patients; and (ii) propensity score adjustment for baseline differences confirmed and lent further support to the finding that HD is strongly associated with cardiac death and TLR after SES implantation.
Clinical and angiographic characteristics
Overall, HD patients had a lower LVEF, higher incidence of DM, and multi-vessel disease, which are known to be negative prognostic factors, and had a high prevalence of peripheral vascular disease indicating extensive atherosclerosis in these patients. Our findings are consistent with those of several other studies which reported a higher prevalence of risk factors and comorbidities in HD patients. 22, 23 On the other hand, HD patients had a lower incidence of hyperlipidaemia and obesity in our study. Percutaneous coronary intervention in HD patients was more complex and difficult to perform because of a higher incidence of moderate to severe calcified lesions, eccentric lesions, and more frequent need of high-pressure dilatation and rotational atherectomy compared with PCI of NH patients. Despite the high prevalence of more complex lesions, our study showed that PCI with SES in HD patients is highly feasible with a delivery success rate of 99.8%.
Long-term clinical efficacy
A previous case -control study showed that SES use yielded better results than BMS for prevention of in-stent restenosis after 9 months in HD patients even with long stenting, but the differences were not statistically significant. 24 Two non-randomized singlecentre observational studies with small numbers of HD patients with follow-up of up to 1 year have been recently reported. 25, 26 One study demonstrated a lower rate of in-stent restenosis and TLR and significantly fewer MACE in the SES group compared with the BMS group. 25 In another study, there were no significant differences in restenosis, TLR, and MACE rates between SES and BMS in HD patients. 26 In short, the results have been variable among several studies and remain controversial. 24 -26 There was one study that compared HD and NH patients implanted with drug-eluting stents (DES) in the real world but the study assessed clinical outcomes for 6 months only. 27 To date, there are no data on the long-term efficacy and safety of DES in a study with a large number of HD patients. Although we did not compare SES with BMS in HD patients, TLR rates of 15.8% for the 1 year, 18.2% for the 2 year, and 19.4% for the 3-year follow-ups were acceptable and lower than those for BMS in previous studies in HD patients. 28 In multivariate analysis, moderate to severe calcification was strongly associated with TLR after SES implantation in HD patients. Although this post-marketing surveillance study was not designed to evaluate the precise mechanism of restenosis, this result may be due to any one or more of the following four factors: (i) sirolimus is not effective or the sirolimus dose of SES is insufficient for calcified atherosclerotic lesions; (ii) there is decreased efficacy due to a defect in the polymer; (iii) stent fracture; and (iv) stent under-expansion. The present study did not address in detail the factors involved in in-stent restenosis after SES implantation in HD patients. Therefore, there is no information regarding stent fracture for in-stent restenosis. Although mean minimal luminal diameter and %DS immediately after SES implantation was angiographically similar for HD and NH patients, there is no detailed data analysis with IVUS in the present study. It was reported that under-expansion of stent estimated with IVUS is an important predictor of TLR and ST after DES implantation.
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A contributory factor for TLR in HD patients could be stent under-expansion because of calcified lesions. In addition, we did not investigate restenosis-related stent fracture. 30 Further prospective studies are needed to investigate after DES implantation in HD patients.
Long-term clinical safety
In this study, mortality was high in HD patients, albeit, similar to that of all studied HD patients in the Japanese population with or without cardiovascular complications. 2 Considering the total population, there was no significant difference in ST rates between HD and NH patients, but in the present study HD patients had double the ST rate of NH patients. A previous study showed that renal insufficiency and dialysis are important predictors of ST after DES implantation for up to 9 months. 31 Recently, the J-Cypher registry data showed that the frequency of early, late, and very late ST after DES implantation in the Japanese 32 was notably lower than in Western countries. 33 However, the J-Cypher registry data show that HD and ESRD without HD are independent predictors of late or very late ST for up to 2 years. 32 Although the difference in ST between the two groups did not reach statistical significance in the present study, further study is needed to investigate ST in this subset of patients on HD in the rest of the world.
Study limitations
This was a multi-centre, non-randomized registry, the results of which need to be validated with prospective randomized studies. We compared the results for HD and NH groups after adjustment of the patient's characteristics using a propensity score because the characteristics of HD patients were different from those of NH patients. Intense anti-platelet therapy may be associated with an increased risk of bleeding complications in HD patients who already have a higher tendency for bleeding, both in basal conditions and during HD sessions. We did not have accurate data regarding the rate of bleeding complication and need for transfusion, but there is no difference with respect to the need of hospitalization for major bleeding and transfusion between the two Figure 2 Three-year propensity score-adjusted cumulative incidence of target-lesion revascularization (A) and cardiac death (B) for the haemodialysis group and the non-haemodialysis group.
Comparison of HD and NH patients groups. A randomized comparison with long-term analysis against BMS (including bleeding risk) is needed to investigate the possible net clinical benefit of SES over BMS. Additionally, the percentage of IVUS guidance of PCI in our study was higher than that reported in studies in Western countries. We analysed MACE, TVR, TVF, and ST rates between patients with or without IVUS, between HD patients with or without IVUS, or between NH patients with or without IVUS. There was no difference in the rate of cardiac events between these groups. However, we think these results could be influenced by selection bias because patients without IVUS (angiographic guidance) may have less complex coronary artery disease. We believe IVUS guidance of PCI is a useful technique for improving stent implantation, particularly for complex lesions, although we cannot demonstrate that this imaging modality is useful for complex lesions. Further study is needed to investigate whether IVUS guidance of PCI is a useful technique for improving stent implantation in the particularly high-risk sub-group of HD patients. 34 We confirmed that HD appears to be strongly associated with mortality and repeat revascularization after SES implantation. In this subset of patients on HD, PCI is likely associated with incomplete revascularization, with potential negative impact on outcome. Coronary artery bypass graft surgery may be more efficacious than PCI with DES in this subset, especially in patients with multi-vessel disease. Comparison trial will help to evaluate the efficacy of DES and CABG, and to define the optimal revascularization therapy for HD patients.
Conclusions
Percutaneous coronary intervention with SES in HD patients is feasible but has a higher incidence of repeat revascularization and mortality compared with those in NH patients. Haemodialysis appears to be strongly associated with mortality and repeat revascularization after SES implantation.
